Genetic Variation in TRAF3IP2 (rs13190932)

Summary

Psoriasis is an immune-mediated inflammatory disease that is highly prevalent worldwide, affecting approximately 2-3% of the world population. It is characterized by red, scaly plaques that can appear on various parts of the body, causing significant physical and psychological burden to affected individuals. The Pathogenesis of PsA involves a complex interplay of genetic, immunological, and environmental factors.Genetic studies have identified several susceptibility loci, including HLA-Cw6 and IL23R, which are shared with psoriasis. Additionally, the presence of certain alleles, such as HLA-B27, is associated with a more severe disease course and a higher likelihood of axial involvement.

Eligibility

Inclusion Criteria:

* Patients aged 18 -70years .
* the severity of cutaneous affection is categorized according to PASI score into PASI 7-12 (moderate severity), and PASI \> 12 (severe severity). (15)Confirmed diagnosis: Psoriasis vulgaris (PsV) or psoriatic arthritis (PsA) diagnosed by the Dermatologist or the Rheumatologist.
* Willingness to participate: Signed informed consent.
* Initiating methotrexate (MTX) therapy: For prospective cohort.
* Availability for follow-up: Patients must be willing and able to attend scheduled visit.

Exclusion Criteria:

* Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus).
* Pregnancy and lactation.
* Patients currently undergoing immunosuppressive or systemic therapies.
* Patients with known genetic disorders affect immune system function.
* Patients with liver or kidney impairment.
* Patients with allergy or contraindication to methotrexate.
* Patients with active or uncontrolled infections, including chronic infections like tuberculosis.
* Previous genetic analysis Patients who have previously undergone genetic analysis for the TRAF3IP2 gene polymorphism (rs13190932).

Conditions3

Browse More Trials